Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 1254 • ACR Convergence 2020
Lack of Efficacy of Early Treatment with Hydroxychloroquine in a Group of Hispanics with Primary Sjögren’s Syndrome
Ariana González-Meléndez¹, Patricia Jordán-González¹, Ricardo Gago-Piñero¹, Noemí Varela-Rosario¹, Naydi Pérez-Ríos¹ and Luis Vilá¹, ¹University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: Treatment of primary Sjögren’s syndrome (pSS) with hydroxychloroquine (HCQ) has been evaluated in the past but with conflicting results regarding its efficacy. While earlier…
Abstract Number: 1746 • ACR Convergence 2020
Association of Obesity with Treatment Response to Methotrexate or Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
Dilli Poudel¹, Ted Mikuls², Michael George¹, Bryant England², Grant Cannon³, Brian Sauer⁴ and Joshua Baker¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³Salt Lake City VA Medical Center and University of Utah, Salt Lake City, ⁴University of Utah, Omaha, NE
Background/Purpose: Obesity affects 30-40% of RA patients and is associated with higher clinical disease activity measures and progressive disability. Studies suggest that obesity may be…
Abstract Number: 2012 • ACR Convergence 2020
A Phase IIb, Randomized, Double-blind Study in Patients with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Patients with an Inadequate Response to Methotrexate
Charles Peterfy¹, Maya Buch², Ernest Choy³, Georg Schett⁴, Dana Parsons-Rich⁵, Anand Patel⁶, Yulia Zima⁵, Claire Le Bolay⁷ and Mark Genovese⁸, ¹Spire Sciences, Inc., Boca Raton, FL, ²Centre of Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, United Kingdom, ³CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ⁴Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ⁵EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁶EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, ⁷Merck KGaA, Darmstadt, Germany, ⁸Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Bruton’s tyrosine kinase (BTK) is involved in multiple signalling pathways potentially implicated in rheumatoid arthritis (RA). Evobrutinib is a highly selective, oral BTK inhibitor.…
Abstract Number: 0216 • ACR Convergence 2020
A Subgroup Analysis of Low Disease Activity and Remission from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs
Jacques-Eric Gottenberg¹, Maya Buch², Roberto Caporali³, Grace Wright⁴, Tsutomu Takeuchi⁵, Kenneth Kalunian⁶, Alena Pechonkina⁷, Ying Guo⁷, Shangbang Rao⁸, YingMeei Tan⁸, Robin Besuyen⁹ and Mark Genovese¹⁰, ¹Strasbourg University Hospital, Strasbourg, France, ²Centre of Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, United Kingdom, ³Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ⁴Association of Women in Rheumatology, New York, NY, ⁵Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan, ⁶School of Health Sciences, University of California, La Jolla, ⁷Gilead Sciences, Inc., Foster City, ⁸Gilead Sciences, Inc., Foster City, CA, ⁹Galapagos BV, Leiden, Netherlands, ¹⁰Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Despite effective treatments, many patients (pts) with rheumatoid arthritis (RA) have inadequate responses to biologic DMARDs (bDMARD-IR), highlighting an unmet need. It is unclear…
Abstract Number: 0479 • ACR Convergence 2020
Early DAS Response After DMARD-start Increases Probability of Achieving Sustained DMARD-free Remission in Rheumatoid Arthritis
Marloes Verstappen¹, Ellis Niemantsverdriet², Xanthe Matthijssen², Saskia le Cessie² and Annette van der Helm - van Mil³, ¹Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Sustained DMARD-free remission (SDFR) is increasingly achievable. The pathogenesis underlying SDFR-development is unknown and patient-characteristics at diagnosis poorly explain whether SDFR will be achieved.…
Abstract Number: 0808 • ACR Convergence 2020
Time to Discontinuation of Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients with and Without Methotrexate: Real World Results from a Rheumatoid Arthritis Cohort
Mohammad Movahedi¹, Angela Cesta², Xiuying Li³, Edward C Keystone⁴ and Claire Bombardier⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, Toronto, Canada, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵Institute for Work and Health, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment and is prescribed alone or with methotrexate (MTX). TOFA can…
Abstract Number: 1005 • ACR Convergence 2020
Risk of Non-vertebral Fractures Among Rheumatoid Arthritis Patients Treated with Biologic or Targeted-Synthetic DMARDs: A Multi-Database Comparative Safety Study
Ajinkya Pawar¹, Rishi Desai¹, Mengdong He¹, Lily Bessette¹ and Seoyoung Kim², ¹Brigham and Women's hospital, Boston, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) increases risk of osteoporosis and fractures. However, limited head-to-head comparative data exists on the risk of non-vertebral osteoporotic fractures (NVFs) among…
Abstract Number: 1343 • ACR Convergence 2020
Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database
Philip Mease¹, Pamela Young², David Gruben³, Lara Fallon⁴, Rebecca Germino⁵ and Arthur Kavanaugh⁶, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Pfizer Inc, Collegeville, PA, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Montreal, QC, Canada, ⁵Pfizer Inc, New York, NY, ⁶UC San Diego Health System, San Diego, CA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). It was approved in the US in December 2017 for…
Abstract Number: 1749 • ACR Convergence 2020
Efficacy of Filgotinib in Patients with Rheumatoid Arthritis with Poor Prognostic Factors: Post Hoc Analysis
Daniel Aletaha¹, Rene Westhovens², Cecile Gaujoux-Viala³, Giovanni Adami⁴, Alan Matsumoto⁵, Paul Bird⁶, Osvaldo Daniel Messina⁷, Maya Buch⁸, Beatrix Bartok⁹, Zhaoyu Yin⁹, Ying Guo¹⁰, Thijs Hendrikx¹¹ and Gerd Burmester¹², ¹Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, ²University Hospitals Leuven, Belgium, Leuven, Belgium, ³Department of Rheumatology, CHU Nîmes, University of Montpellier-Nîmes, France, EA2415, University of Montpellier, Montpellier, France, Nîmes, France, ⁴University of Verona, Verona, Italy, ⁵Arthritis and Rheumatism Assoc, Wheaton, MD, ⁶University New South Wales, Sydney, Australia, ⁷IRO Medical Ctr & Cosme Argerich Hospital, Buenos Aires, Argentina, ⁸Centre of Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, United Kingdom, ⁹Gilead Sciences, Inc., Foster City, CA, ¹⁰Gilead Sciences, Inc., Foster City, ¹¹Galapagos BV, Leiden, Netherlands, ¹²Charité University Hospital Berlin, Berlin, Germany
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) with poor prognostic factors (PPF) are at risk for RA progression if disease activity is not rapidly controlled.…
Abstract Number: 0217 • ACR Convergence 2020
Efficacy and Safety of Filgotinib in Methotrexate-Naïve Patients with Rheumatoid Arthritis: 52-Week Results
Rene Westhovens¹, William F. C. Rigby², Désirée van der Heijde³, Daniel W.T. Ching⁴, William Stohl⁵, Jonathan Kay⁶, Arvind Chopra⁷, Beatrix Bartok⁸, Franziska Matzkies⁸, Zhaoyu Yin⁸, Ying Guo⁹, Chantal Tasset¹⁰, John S. Sundy⁸, Angelika Jahreis⁸, Neelufar Mozaffarian¹¹, Osvaldo Daniel Messina¹², Robert Landewé¹³, Tatsuya Atsumi¹⁴ and Gerd Burmester¹⁵, ¹University Hospitals Leuven, Belgium, Leuven, Belgium, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Timaru Hospital, Timaru, New Zealand, ⁵University of Southern California Keck School of Medicine, Los Angeles, CA, ⁶University of Massachusetts Medical School, Worcester, MA, ⁷Center for Rheumatic Diseases, Pune, India, ⁸Gilead Sciences, Inc., Foster City, CA, ⁹Gilead Sciences, Inc., Foster City, ¹⁰Galapagos NV, Mechelen, Belgium, ¹¹Ichnos Sciences, Paramus, ¹²IRO Medical Ctr & Cosme Argerich Hospital, Buenos Aires, Argentina, ¹³Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ¹⁴Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan, ¹⁵Charité University Hospital Berlin, Berlin, Germany
Background/Purpose: Filgotinib (FIL) is an oral, potent, selective JAK 1 inhibitor. FINCH 3 assessed FIL efficacy and safety in methotrexate (MTX)-naïve patients (pts) with rheumatoid…
Abstract Number: 0484 • ACR Convergence 2020
Relationship Between Paraoxonase-1 Genotype, Activity, and Major Adverse Cardiovascular Events in Patients with Rheumatoid Arthritis Receiving Tofacitinib
Christina Charles-Schoeman¹, Craig Hyde², Shunjie Guan³, Neil Parikh¹, Jennifer Wang¹, Ani Shahbazian¹, Lori Stockert⁴ and John Andrews⁴, ¹University of California, Los Angeles, Los Angeles, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Cambridge, MA, ⁴Pfizer Inc, Collegeville, PA
Background/Purpose: Paraoxonase 1 (PON1) is a high-density lipoprotein (HDL)‑associated enzyme with paraoxonase, lactonase, and arylesterase activities. PON1 contributes to the antioxidant properties of HDL, and…
Abstract Number: 0815 • ACR Convergence 2020
Initial Pharmaceutical Management in a National Cohort of Elderly-Onset Rheumatoid Arthritis Patients
Deepan Dalal¹, Tingting Zhang², Hiren Varma² and Theresa Shireman², ¹Brown University, East Providence, RI, ²Brown University, Providence, RI
Background/Purpose: Methotrexate is the preferred initial drug for treatment of rheumatoid arthritis (RA) per American College of Rheumatology guidelines (2015). People with elderly-onset RA, classified as onset…
Abstract Number: 1010 • ACR Convergence 2020
Infection and Malignancy Outcomes in Patients with RA Treated with Abatacept: Results from a Multinational Surveillance Study
Alyssa Dominique¹, Merete Hetland², Axel Finckh³, Jacques-Eric Gottenberg⁴, Florenzo Iannone⁵, Roberto Caporali⁶, Dan Nordstrom⁷, M Victoria Hernandez⁸, Carlos Sanchez-Piedra⁹, Fernando Sanchez-Alonso⁹, Karel Pavelka¹⁰, Zlatuše Křístková¹¹ and Teresa Simon¹², ¹Bristol-Myers Squibb Company, Princeton, NJ, ²The DANBIO Registry, Rigshospitalet, Glostrup, Denmark, ³Division of Rheumatology, University Hospitals of Geneva, Geneva, Switzerland, ⁴Strasbourg University Hospital, Strasbourg, France, ⁵DETO-Rheumatology Unit, University of Bari, Bari, Italy, ⁶Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ⁷Helsinki University Hospital and Helsinki University, Helsinki, Finland, ⁸Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain, ⁹Biobadaser, Research Unit, Sociedad Española de Reumatología, Madrid, Spain, ¹⁰Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹¹Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic, ¹²Bristol-Myers Squibb Company (at time of analysis), Princeton, NJ
Background/Purpose: Compared with the general population, patients with RA are at an increased risk of infection and certain malignancies, which may be increased further with…
Abstract Number: 1348 • ACR Convergence 2020
What Influence Do Clinical Domains Other Than Arthritis Have on Composite Clinical Outcomes in Psoriatic Arthritis?: Comparison of Treatment Effects in the SEAM-PsA Trial
Philip Helliwell¹, Philip Mease², Arthur Kavanaugh³, Laura Coates⁴, Alexis Ogdie⁵, Atul Deodhar⁶, Vibeke Strand⁷, Ervant Maksabedian⁸, Gregory Kricorian⁹, Lyrica Liu⁹, David Collier¹⁰ and Dafna Gladman¹¹, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³UC San Diego Health System, San Diego, CA, ⁴University of Oxford, Oxford, United Kingdom, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Oregon Health & Science University, Portland, OR, ⁷Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁸Amgen Inc., LOS ANGELES, CA, ⁹Amgen Inc., Thousand Oaks, CA, ¹⁰Amgen, Thousand Oaks, CA, ¹¹Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis is broadly characterized by clinical domains such as enthesitis, dactylitis, nail manifestations, and psoriasis. How these clinical domains influence the response to…
Abstract Number: 1752 • ACR Convergence 2020
Prediction of Responder and Non-responder to JAK Inhibitors in Patients with Rheumatoid Arthritis: A Pilot Study with Integrative Cluster Analysis
Masanari Sugawara¹, Yuichiro Fujieda², Atsushi Noguchi³, Shun Tanimura⁴, Yuka Shimizu⁵, Ikuma Nakagawa⁶, Hiroki Takahashi⁷, Michihito Kono⁸, Masaru Kato², Kenji Oku², Olga Amengual² and Tatsuya Atsumi⁹, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo city, Hokkaido, Japan, ²Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ³Department of Internal Medicine and General Medicine, Japanese Red Cross Kitami Hospital, Sapporo, Japan, ⁴Department of Internal Medicine, Tomakomai City Hospital, Tomakomai, Hokkaido, Japan, ⁵3rd Department of Internal medicine, Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital, Sapporo, Japan, ⁶Department of Internal Medicine, Takikawa Municipal Hospital, Sapporo, Japan, ⁷Department of Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan, ⁸Department of Rheumatology, Endocrinology and Nephrology, Graduate School of Medicine and Faculty of Medicine, Hokkaido University, Sapporo, Japan, ⁹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan
Background/Purpose: [Background]Oral Janus kinase inhibitors (JAKi) show dramatical efficacy to reduce the disease activity in patients with rheumatoid arthritis (RA). However, there remain some　patients who…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].